Camillo Ricordi, MD
Camillo Ricordi, MD, Stacy Joy Goodman Professor of Surgery, Medicine, Biomedical Engineering, Microbiology and Immunology
Dr. Camillo Ricordi is Professor and Chief of the Division of Cellular Transplantation, Department of Surgery and Director of the Diabetes Research Institute at the University of Miami. Dr. Ricordi served as president of the Cell Transplant Society and the International Islet and Pancreas Transplant Association, as councilor of American Society of Transplant Surgeons and The Transplantation Society. He has served on several NIH Expert Panels, Strategic Planning committees, NCRR ICR Executive Committee and is currently chairperson of the steering committee of the NIH Clinical Islet Transplantation consortium; Ricordi serves also as President of the Board of both ISMETT (Mediterranean Institute for Transplantation and Advanced Therapies) and Ri.MED Foundation. Honors and awards include the 2001 World Prize of Surgery (University of Geneva), the Outstanding Scientific Achievement Award (2002 Lilly Lecture, ADA Congress) and delivered the opening plenary (Galileo Lecture) at the European Association for the Study of Diabetes (EASD) Congress in Rome (2008). In 2009 Dr. Ricordi was Knighted by the President of the Republic of Italy in the highest Order of the Republic (the Order of Merit) with the Knighthood decoration of Cavaliere Ufficiale and in 2010 he was only surgeon and one of the few ever inducted into theAssociation of American Physicians (AAP). Dr. Ricordi is currently serving on the editorial boards of CellR4 (Editor-in-Chief) and Cell Transplantation (Co-Editor-in-Chief). Dr. Ricordi also serves as President of The Cure Alliance and Chairman of the Diabetes Research Institute Federation, coordinating and promoting cure focused research at over 24 leading institutions worldwide, while further developing Telescience platform technologies to eliminate geographic barriers to scientific collaboration. Dr. Ricordi has authored over 700 scientific publications, and as an inventor, he has been awarded 19 patents.
SYNOPSIS OF AREA OF INTEREST: Development of cell therapy technologies and tolerance induction strategies for transplantation without continuous immunosuppression, and development of unlimited sources of insulin producing tissue (from xenografts to stem cells).
DETAILED AREA OF INTEREST: Dr. Ricordi's research objective is to develop a cure for Type 1 Diabetes, and he is known for pioneering islet isolation techniques that are now used worldwide and for performing the first successful series of human islet allografts. He contributed to the development of the first cGMP human islet cell processing facilities and to the standardization of human cell processing and transplant techniques protocols, from pre-clinical model systems to FDA Phase I/II and Phase III clinical trials. His major interests include the definition of strategies for immune tolerance induction, performing the first NIH funded, randomized prospective trials of donor bone marrow cell infusions to enhance allograft survival and most recently infusions of positively selected donor CD34+ cells with the objective to induce chimerism and avoid the need for chronic recipient immunosuppression. Dr. Ricordi and collaborators recently completed the first FDA Phase 3 multicenter trial of islet transplantation in the most severe cases of Type 1 Diabetes. Research interests also include the development of effective strategies for manipulation of the micro-environment at the transplant site, to enhance initial post-transplant engraftment. Recent research also focuses on the development of effective ectopic transplant sites, through organ and tissue engineering, the use of hybrid devices for cell therapy with local immunomodulation and/or immunosuppression, and novel strategies for microencapsulation for immunoprotection. On the technology side, research interests include the development of automated methods for cell separation, remotely controlled cell processing equipment and telescience capability, new platform technologies for large scale cell culture, shipment of cell products across state barriers and the definition of novel pre-transplant potency tests that could predict post-transplant outcome.